Targeted Immune Modulation
A randomized trial of methylprednisolone found no significant difference in atrial fibrillation recurrence after 24 months. Colchicine has shown effectiveness in atrial fibrillation prevention, especially after pulmonary vein isolation, bu…
1 sources - 5 claims
A randomized trial of methylprednisolone found no significant difference in atrial fibrillation recurrence after 24 months. Colchicine has shown effectiveness in atrial fibrillation prevention, especially after pulmonary vein isolation, but adverse drug reactions limit its use. European Society of Cardiology atrial fibrillation guidelines do not recommend immunomodulators because positive randomized controlled trials are lacking. No definitive druggable immune target for atrial fibrillation has been identified. Future targeted immune modulation around ablation could focus on IL-6 and IL-11 pathways, especially in persistent atrial fibrillation.